Meeting
2015 ASCO Annual Meeting
Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.
Authors
Michael J. Donovan
Icahn School of Medicine at Mount Sinai, New York, NY
Michael J. Donovan , Mikkel Noerholm , Stefan Bentink , Susan Belzer , Johan Skog , Gordon Andrew Brown , James S. Cochran , Vince O'Neill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5064)
DOI
10.1200/jco.2015.33.15_suppl.5064
Abstract #
5064
Poster Bd #
58
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate needle biopsy.
First Author: Michael J. Donovan
Poster
2016 Genitourinary Cancers Symposium
A non-invasive urine exosome gene expression assay (ExoIntelliScore Prostate) to predict pathologic stage and grade in the prostatectomy specimen.
First Author: Michael Donovan
Poster
2020 ASCO Virtual Scientific Program
A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.
First Author: Liaoyuan Li
Poster
2019 Genitourinary Cancers Symposium
SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.
First Author: Gretchen Hoyer